Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04853004

Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare With Regard to Vaccinations

Studies of Ongoing and Completed SARS-CoV-2 Infection (Which Causes COVID-19) Within the Healthcare in Stockholm County, With Regard to Vaccinations.

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
10,000 (estimated)
Sponsor
Karolinska Institutet · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

To investigate the incidence of SARS-CoV-2 infections after vaccination, to monitor the development of SARS-CoV-2 antibody levels after vaccination and to compare this in relation to both previous health \& disease, previous antibody responses and in relation to future disease occurring after vaccination.

Detailed description

The purpose of the study is to analyze the effect of and possible side effects of SARS-CoV2 vaccinations in the cohort study where data on sick leave, SARS-Cov2 infections and SARS-CoV2 antibody levels are well documented even before vaccination. The main outcome measures are the presence of SARS-CoV-2 (ongoing infection) and the presence of antibodies to SARS-CoV-2. For the vaccination effect, the factors that are primarily associated with protection against infection are analyzed, such as age, sex, workplace, antibody response to SARS-CoV-2 and vaccination date. The analyzes are planned to be performed with multivariate logistic regression with Relative Risk as the outcome measure. Data from the analysis of virus antibodies are planned to be performed divided into whether low, medium or high levels of antibodies occur, with the same analysis for possible association with the factors listed above.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTSARS-CoV2 antibody measurementBlood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.

Timeline

Start date
2021-04-01
Primary completion
2023-03-31
Completion
2025-12-31
First posted
2021-04-21
Last updated
2025-03-20

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT04853004. Inclusion in this directory is not an endorsement.